Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Autophagy is an evolutionarily conserved cellular degradation process that targets cytoplasmic materials—including proteins, macromolecules, and unwanted organelles—for lysosome-dependent breakdown. It is essential for maintaining cellular homeostasis by removing damaged components and recycling nutrients during periods of stress such as starvation or hypoxia. There are three main types—macroautophagy (the most studied), microautophagy, and chaperone-mediated autophagy—each with distinct mechanisms but all serving the purpose of intracellular quality control. Autophagic dysfunction is implicated in various diseases including cancer, neurodegenerative disorders, infections, and aging-related conditions. The process involves several key steps: initiation by stress signals; nucleation via complexes like Beclin1-VPS34; elongation involving ATG proteins; fusion with lysosomes; followed by degradation/recycling of cargo. While critical for cell survival under adverse conditions, dysregulation can have pathological consequences.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular autophagy process.